Clinical Trial

Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Neoadjuvant plus adjuvant treatment with immunotherapy may have an anti-tumor activity and reduce the risk of relapse in patients with high risk surgically resectable stage III cutaneous squamous cell carcinoma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-11-11; most recent amendment 2025-03-11.
Status change: Recruiting → Active, Not Recruiting 2023-02-20
Status change: Not Yet Recruiting → Recruiting 2021-04-23
Trial Details
NCT Number NCT04632433
Lead Sponsor Fondazione Melanoma Onlus
Conditions Cutaneous Squamous Cell Carcinoma
Enrollment 25 participants
Start Date 2021-02-10
Primary Completion 2023-02-06 (estimated)
Study Completion 2026-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-13